Evidence map›Paper›PMID 38148046›Full record

ArticleIn vivo (Athens, Greece)

Serum-based Comprehensive

Xin Jin, Weibin Zhang, Qing Han, Qinying Li, Jinbao Zong, Xiaoyu Li, Chen Wang, Hao Jiang, Guangli Yu, Guoyun Li

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 67% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Xin Jin *Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Shandong Key Laboratory of Glycoscience and Glycotechnology, Ocean University of China, Qingdao, P.R. China.
Weibin Zhang *Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Shandong Key Laboratory of Glycoscience and Glycotechnology, Ocean University of China, Qingdao, P.R. China.
Qing Han *Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Shandong Key Laboratory of Glycoscience and Glycotechnology, Ocean University of China, Qingdao, P.R. China.
Qinying LiKey Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Shandong Key Laboratory of Glycoscience and Glycotechnology, Ocean University of China, Qingdao, P.R. China.
Jinbao ZongThe Affiliated Hospital of Qingdao University, Qingdao, P.R. China.
Xiaoyu LiThe Affiliated Hospital of Qingdao University, Qingdao, P.R. China.
Chen WangKey Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Shandong Key Laboratory of Glycoscience and Glycotechnology, Ocean University of China, Qingdao, P.R. China.
Hao JiangKey Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Shandong Key Laboratory of Glycoscience and Glycotechnology, Ocean University of China, Qingdao, P.R. China; haojiang@ouc.edu.cn.
Guangli YuKey Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Shandong Key Laboratory of Glycoscience and Glycotechnology, Ocean University of China, Qingdao, P.R. China.
Guoyun LiKey Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Shandong Key Laboratory of Glycoscience and Glycotechnology, Ocean University of China, Qingdao, P.R. China; liguoyun@ouc.edu.cn.
Ocean University of China · CNQingdao University · CNQingdao National Laboratory for Marine Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimN-glycans are potential serum biomarkers due to their aberrant structure and abundance alteration during disease progression. Few studies have been associated with relative quantitative N-glycans profiling during different gastric disease stages. In this study, we conducted an investigation on the profiling of N-glycans in patients with gastric disease, as well as in healthy controls. MATERIALS AND

methodsIn this study, the porous graphitization carbon chromatography-high resolution Fourier transform mass spectrometry (PGC-FTMS) method was applied to assess comprehensive N-glycans profiling in patients at different stages of gastric disease, including gastritis, atrophic gastritis, gastric ulcer, gastric polyps, and gastric cancer.

resultsA total of 45 N-glycans (relative abundance >0.1%) were detected, and 9 N-glycans were found to be potential biomarkers for gastric disease detection. Along with the progression of gastric disease, the abundance of sialylated N-glycans increased, while that of core-fucosylated N-glycans decreased. Multivariate statistical analysis demonstrated that N-glycans profiling between gastritis and healthy controls had significant differences. The characteristic N-glycans distinguished gastric cancer from healthy controls, which had strong clinical diagnostic value.

conclusionThe relative quantitative profile of N-glycans in different gastric disease stages was revealed and serum N-glycans are proposed for distinguishing gastric disease stages in clinical application.

Indexed as

GastritisStomach NeoplasmsBiomarkers, TumorCarbonHumansLiquid Chromatography-Mass SpectrometryPolysaccharidesPorosityBiomarkers, TumorCarbonPolysaccharidesbiomarkerGastric diseaseN-glycansporous graphitic carbon liquid chromatography-mass spectrometryserum

Identifiers

PMID38148046
PMCPMC10756461
OpenAlexW4390234324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.